Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BLUNASDAQ:EVFMNASDAQ:NXTCNASDAQ:TFFP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLUBELLUS Health$14.74$14.62$6.38▼$14.76$1.87B0.193.08 million shs3.45 million shsEVFMEvofem Biosciences$0.01+4.2%$0.02$0.01▼$3.75$821K-1.12774,904 shs239,394 shsNXTCNextCure$1.35+4.7%$1.74$0.98▼$2.57$37.67M0.4230,813 shs25,510 shsTFFPTFF Pharmaceuticals$3.10+1.6%$5.94$2.51▼$21.25$7.81M1.2927,905 shs2,142 shsBeginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLUBELLUS Health0.00%0.00%0.00%0.00%+1.80%EVFMEvofem Biosciences-4.70%+0.71%-21.98%-59.31%-99.44%NXTCNextCure-10.42%-17.83%-34.52%+1.57%-13.42%TFFPTFF Pharmaceuticals+1.33%-2.71%-53.00%-39.36%-78.78%He Is Giving Away Bitcoin (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLUBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ANXTCNextCure4.6573 of 5 stars3.55.00.04.62.51.71.3TFFPTFF Pharmaceuticals2.6605 of 5 stars3.55.00.00.02.80.00.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLUBELLUS HealthN/AN/AN/AN/AEVFMEvofem Biosciences2.00HoldN/AN/ANXTCNextCure3.00Buy$6.00344.44% UpsideTFFPTFF Pharmaceuticals3.00Buy$72.002,222.58% UpsideCurrent Analyst RatingsLatest NXTC, BLU, EVFM, and TFFP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024TFFPTFF PharmaceuticalsRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $44.003/22/2024NXTCNextCureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $8.003/20/2024NXTCNextCureNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLUBELLUS Health$15K124,613.93N/AN/A$3.09 per share4.77EVFMEvofem Biosciences$18.22M0.05$1.48 per share0.01($2.64) per share-0.01NXTCNextCureN/AN/AN/AN/A$4.10 per shareN/ATFFPTFF Pharmaceuticals$730K10.70N/AN/A$4.04 per share0.77Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLUBELLUS Health-$76.08M-$0.72N/AN/AN/A-578,586.63%-24.27%-23.14%N/AEVFMEvofem Biosciences$52.98M-$7.62N/A∞N/A290.81%-90.20%331.20%4/26/2024 (Estimated)NXTCNextCure-$62.72M-$2.25N/AN/AN/AN/A-47.03%-42.59%5/2/2024 (Estimated)TFFPTFF Pharmaceuticals-$21.24M-$12.51N/AN/AN/A-2,897.95%-163.14%-144.77%5/9/2024 (Estimated)Latest NXTC, BLU, EVFM, and TFFP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023TFFPTFF Pharmaceuticals-$2.00-$2.01-$0.01-$2.01$0.20 million$0.11 million3/27/2024Q4 2023EVFMEvofem BiosciencesN/A-$0.44-$0.44-$0.44N/A$4.84 million3/21/2024Q4 2023NXTCNextCure-$0.54-$0.52+$0.02-$0.52N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLUBELLUS HealthN/AN/AN/AN/AN/AEVFMEvofem BiosciencesN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLUBELLUS HealthN/A33.4233.42EVFMEvofem BiosciencesN/A0.130.10NXTCNextCureN/A16.3816.38TFFPTFF PharmaceuticalsN/A3.123.12OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLUBELLUS Health90.37%EVFMEvofem Biosciences0.22%NXTCNextCure42.65%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipBLUBELLUS Health24.17%EVFMEvofem Biosciences0.21%NXTCNextCure11.90%TFFPTFF Pharmaceuticals5.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBLUBELLUS Health74126.81 million96.16 millionNot OptionableEVFMEvofem Biosciences3755.46 million53.85 millionNot OptionableNXTCNextCure8227.90 million24.58 millionOptionableTFFPTFF Pharmaceuticals192.52 million2.38 millionOptionableNXTC, BLU, EVFM, and TFFP HeadlinesSourceHeadlineTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99msn.com - April 17 at 11:27 PMTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation Powdermarkets.businessinsider.com - April 15 at 9:43 AMTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract Sessionsglobenewswire.com - April 15 at 7:00 AMTFF Pharmaceuticals Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - April 1 at 10:13 AMTFF Pharmaceuticals reports positive phase 2 trial resultsinvesting.com - March 29 at 11:52 PMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsfinanznachrichten.de - March 29 at 8:50 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023investorplace.com - March 28 at 11:31 PMTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 28 at 4:05 PMTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programsglobenewswire.com - March 27 at 4:01 PMTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingglobenewswire.com - March 25 at 9:01 AMTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 22 at 3:11 PMTFF Pharmaceuticals, Inc. (TFFP)finance.yahoo.com - March 21 at 9:12 PMTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 20 at 12:00 PMTFF Pharmaceuticals Announces Update on Clinical Programsglobenewswire.com - March 20 at 9:03 AMTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024globenewswire.com - March 14 at 4:47 PMTff Pharmaceuticals Inc (TFFP)uk.investing.com - March 12 at 6:49 PMTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conferencefinance.yahoo.com - January 24 at 10:43 AMTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingfinance.yahoo.com - January 9 at 10:39 AMTFF Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 5 at 1:08 PMPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price Targetmarkets.businessinsider.com - December 21 at 8:22 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023investorplace.com - December 20 at 11:12 AMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACfinanznachrichten.de - December 19 at 8:56 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioStock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a monthApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft push Wall Street toward its first winning week in a month5 High Short Interest Stocks Getting Squeezed With Upside To GoApril 5, 2024 9:25 AMView 5 High Short Interest Stocks Getting Squeezed With Upside To GoBuy the Dip in Netflix Stock, It Won’t Last LongApril 19, 2024 8:32 AMView Buy the Dip in Netflix Stock, It Won’t Last LongComprehensive PepsiCo Stock AnalysisApril 18, 2024 12:05 PMView Comprehensive PepsiCo Stock AnalysisAll Headlines Company DescriptionsBELLUS HealthNASDAQ:BLUBELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.Evofem BiosciencesNASDAQ:EVFMEvofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.NextCureNASDAQ:NXTCNextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.